Selected research
Industry Research
Multiple Sclerosis Drugs Industry Research Report 2026
Market perspective
The global Multiple Sclerosis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Multiple Sclerosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Multiple Sclerosis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Multiple Sclerosis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Multiple Sclerosis Drugs include ACORDA, Biogen, Mallinckrodt, Bayer, Merck KGaA, Novartis, Sanofi and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Multiple Sclerosis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Multiple Sclerosis Drugs Market by Company
ACORDA
Biogen
Mallinckrodt
Bayer
Merck KGaA
Novartis
Sanofi
Teva
Multiple Sclerosis Drugs Segment by Type
Injectable Medications
Oral Medications
Others
Multiple Sclerosis Drugs Segment by Application
Adults
Children
Multiple Sclerosis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Multiple Sclerosis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Multiple Sclerosis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Multiple Sclerosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injectable Medications
- Oral Medications
- Others
Applications
- Adults
- Children
Companies covered
- ACORDA
- Biogen
- Mallinckrodt
- Bayer
- Merck KGaA
- Novartis
- Sanofi
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Multiple Sclerosis Drugs Market Size (2021-2032)
- 2.2.2 Global Multiple Sclerosis Drugs Sales (2021-2032)
- 2.2.3 Global Multiple Sclerosis Drugs Market Average Price (2021-2032)
- 2.3 Multiple Sclerosis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injectable Medications
- 2.3.3 Oral Medications
- 2.3.4 Others
- 2.4 Multiple Sclerosis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Multiple Sclerosis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Multiple Sclerosis Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Multiple Sclerosis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Multiple Sclerosis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Multiple Sclerosis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Multiple Sclerosis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Multiple Sclerosis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Multiple Sclerosis Drugs, Established Date
- 3.9 Global Multiple Sclerosis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ACORDA
- 4.1.1 ACORDA Company Information
- 4.1.2 ACORDA Business Overview
- 4.1.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ACORDA Multiple Sclerosis Drugs Product Portfolio
- 4.1.5 ACORDA Recent Developments
- 4.2 Biogen
- 4.2.1 Biogen Company Information
- 4.2.2 Biogen Business Overview
- 4.2.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biogen Multiple Sclerosis Drugs Product Portfolio
- 4.2.5 Biogen Recent Developments
- 4.3 Mallinckrodt
- 4.3.1 Mallinckrodt Company Information
- 4.3.2 Mallinckrodt Business Overview
- 4.3.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio
- 4.3.5 Mallinckrodt Recent Developments
- 4.4 Bayer
- 4.4.1 Bayer Company Information
- 4.4.2 Bayer Business Overview
- 4.4.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bayer Multiple Sclerosis Drugs Product Portfolio
- 4.4.5 Bayer Recent Developments
- 4.5 Merck KGaA
- 4.5.1 Merck KGaA Company Information
- 4.5.2 Merck KGaA Business Overview
- 4.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio
- 4.5.5 Merck KGaA Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Multiple Sclerosis Drugs Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Sanofi
- 4.7.1 Sanofi Company Information
- 4.7.2 Sanofi Business Overview
- 4.7.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sanofi Multiple Sclerosis Drugs Product Portfolio
- 4.7.5 Sanofi Recent Developments
- 4.8 Teva
- 4.8.1 Teva Company Information
- 4.8.2 Teva Business Overview
- 4.8.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Multiple Sclerosis Drugs Product Portfolio
- 4.8.5 Teva Recent Developments
5 Global Multiple Sclerosis Drugs Market Scenario by Region
- 5.1 Global Multiple Sclerosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Multiple Sclerosis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Multiple Sclerosis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Multiple Sclerosis Drugs Sales by Region: 2027-2032
- 5.3 Global Multiple Sclerosis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Multiple Sclerosis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Multiple Sclerosis Drugs Revenue by Region: 2027-2032
- 5.4 North America Multiple Sclerosis Drugs Market Facts & Figures by Country
- 5.4.1 North America Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Multiple Sclerosis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Multiple Sclerosis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Multiple Sclerosis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Multiple Sclerosis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Multiple Sclerosis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Multiple Sclerosis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Multiple Sclerosis Drugs Market Facts & Figures by Country
- 5.7.1 South America Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Multiple Sclerosis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Multiple Sclerosis Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Multiple Sclerosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Multiple Sclerosis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Multiple Sclerosis Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Multiple Sclerosis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Multiple Sclerosis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Multiple Sclerosis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Multiple Sclerosis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Multiple Sclerosis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Multiple Sclerosis Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Multiple Sclerosis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Multiple Sclerosis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Multiple Sclerosis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Multiple Sclerosis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Multiple Sclerosis Drugs Value Chain Analysis
- 8.1.1 Multiple Sclerosis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Multiple Sclerosis Drugs Production Mode & Process
- 8.2 Multiple Sclerosis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Multiple Sclerosis Drugs Distributors
- 8.2.3 Multiple Sclerosis Drugs Customers
9 Global Multiple Sclerosis Drugs Analyzing Market Dynamics
- 9.1 Multiple Sclerosis Drugs Industry Trends
- 9.2 Multiple Sclerosis Drugs Industry Drivers
- 9.3 Multiple Sclerosis Drugs Industry Opportunities and Challenges
- 9.4 Multiple Sclerosis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst